Study says booster dose of Covid vaccine could cut 90% of deaths

A study conducted by researchers from different institutions in Hong Kong and published in the scientific journal Journal of the Canadian Medical Associationregistered air90% reduction in deaths after administration of only one in people with multimorbidity (multiple comorbidities) booster dose Opposite COVID-19 – compared to those taking only the first two doses.

From the survey data, scientists suggest that mass vaccination plays an important role in mortality during the pandemic, especially in people with comorbidities. The highest death rate was recorded in Hong Kong at the end of 2021, but began to decline in early 2022 as healthcare workers and priority groups began taking booster doses.

The study suggests that boosters are important for the elderly and people with chronic diseases, in addition to those with comorbidities, and points out that future booster vaccines are important for reducing deaths, not just for the third dose.

“We found that the risk of death associated with COVID-19 was significantly reduced in adults with multimorbidity who received a homologous booster dose of BNT162b2, an mRNA vaccine, or CoronaVac, an inactivated whole virus vaccine. These results support the efficacy of booster vaccine doses in those with multimorbidity across the micron epidemic. from 2 different technology platforms in reducing mortality,” the authors explain in the study.

Efficacy of the third dose

To conduct the research, the scientists used data from more than 120,000 people who received Pfizer-BioNTech’s homologous doses of the vaccine (87,000 with the booster) and more than 127,000 people who received the CoronaVac (94,000 with the booster). They found that more deaths occurred in individuals vaccinated with CoronaVac.

As the researchers explain, the study provides solid data suggesting that increasing coronavirus vaccines could reduce the death rate, especially in people with different chronic conditions such as high blood pressure, diabetes and kidney disease.

However, they point out that since the tests were mostly done in Chinese, more research is needed to understand booster dose in other populations to generalize the finding. At the end of the study, the statement “The analysis should be repeated to test generalizability to other populations” is explained.